

## Monoclonal antibody against BRAF V600K mutation (P-1287)

### Keywords

- Antibody that specifically detects the V600K mutation of human BRAF protein
- Monoclonal mouse antibody, IgG2b subtype
- Tested for Western Blot and IHC

### Abstract

Approximately 7% of all human tumors show mutations in the proto-oncogene BRAF at position 600. Besides the V600E mutation, V600K is the second most common mutation at position 600. For example, most melanomas contain BRAF mutations, with incidences of approximately 90% and 8%, respectively, for BRAF V600E and BRAF V600K.

DKFZ has developed a mouse monoclonal antibody of IgG2b subtype that is capable of detecting BRAF protein mutated at position 600 (V600K) in Western Blot and IHC analysis.

### Development Stage

Hybridoma cell line established; Antibody tested in Western Blot and IHC experiments.

### The Technology

A monoclonal mouse hybridoma cell line was created using a protocol similar to that of Köhler and Milstein.

### Applications and Commercial Opportunity

DKFZ is looking for a commercial partner to produce and distribute the monoclonal antibody for research, diagnostic and R&D purposes.

### Inventors

The investigators are: Claudia Tessmer and Ulrike Ackermann, both at DKFZ.

### Intellectual Property

A German utility model has been filed. Priority date: 2.6.2016

### Further Information

No other public information is currently available, but further information (speaking with the inventor) is available under a signed Confidential Disclosure Agreement (CDA).

### DKFZ Contact:

For further information, including a CDA, please contact:

Dr. Frieder Kern  
Deutsches Krebsforschungszentrum  
Technology Transfer Office T010  
Email: F.Kern@dkfz.de  
Tel.: +49-(0)6221-42-2952  
Fax: +49-(0)6221-42-2956

### Figure 1:

Western Blot analysis using transduced HEK cells demonstrating the selectiveness of the antibody for the K-variant of the mutation V600:

